952 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Bayesian Capital Management LP

Bayesian Capital Management LP purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 952 shares of the biopharmaceutical company's stock, valued at approximately $678,000.

Other hedge funds also recently made changes to their positions in the company. Capital International Investors grew its position in shares of Regeneron Pharmaceuticals by 41.6% during the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock worth $3,373,859,000 after buying an additional 1,390,534 shares during the period. Geode Capital Management LLC grew its position in Regeneron Pharmaceuticals by 6.8% in the 4th quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company's stock valued at $1,726,940,000 after purchasing an additional 155,369 shares during the period. Dodge & Cox grew its position in Regeneron Pharmaceuticals by 0.4% in the 4th quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company's stock valued at $1,653,543,000 after purchasing an additional 9,381 shares during the period. Price T Rowe Associates Inc. MD grew its position in Regeneron Pharmaceuticals by 63.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock valued at $1,485,527,000 after purchasing an additional 810,144 shares during the period. Finally, Franklin Resources Inc. grew its position in Regeneron Pharmaceuticals by 7.9% in the 4th quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company's stock valued at $1,456,864,000 after purchasing an additional 149,124 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN traded up $40.19 during mid-day trading on Monday, reaching $567.97. The company's stock had a trading volume of 702,262 shares, compared to its average volume of 769,992. Regeneron Pharmaceuticals, Inc. has a 12-month low of $517.05 and a 12-month high of $1,211.20. The firm's fifty day moving average price is $613.08 and its two-hundred day moving average price is $693.43. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The stock has a market cap of $62.09 billion, a P/E ratio of 14.82, a PEG ratio of 2.34 and a beta of 0.43.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. During the same period in the previous year, the company earned $9.55 EPS. Regeneron Pharmaceuticals's revenue for the quarter was down 3.7% compared to the same quarter last year. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.62%. The ex-dividend date of this dividend is Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is 8.96%.

Analyst Ratings Changes

Several analysts recently issued reports on REGN shares. Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 5th. Canaccord Genuity Group raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 22nd. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 1st. Robert W. Baird cut their price objective on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a report on Friday, April 25th. Finally, Royal Bank of Canada cut their price objective on shares of Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an "outperform" rating on the stock in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, five have issued a hold rating, eighteen have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $892.60.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.